Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity

Assiut University

Status: Unknown

Conditions: Covid19

Treatments: Drug: DAAD Compound

Study type: Observational

Funder types: Other

Identifiers

NCT04729153

DAADs and covid-19

Details and patient eligibility

About

Evaluate effect of DAADs on covid-19 disease.

Full description

If Chronic HCV patients who already received DAADs are protected against covid 19 and considered to be immune or not And if DAADS can be used in ttt of covid 19

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. HCV patient with or without LC.
2. >18 years old.
3. Received DAADs at 2019.

Exclusion criteria

1. Combined HCV and HIV infected patients.
2. Combined HCV and HBV infected patients.
3. < 18 years old.
4. Pregnant or breast-feeding patients.
5. Patients with autoimmune disease.
6. Patients with multiorgan failure, active cancer, renal insufficiency.
7. Patients received immunosuppressive drugs.
8. Immune compromised patients.
9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.

Trial design

100 participants in 2 patient groups

Chronic HCV patients previously treated by DAADs.

Treatment:

Drug: DAAD Compound

Chronic HCV patients not treated by DAADs yet.